1. Home
  2. HNVR vs MOLN Comparison

HNVR vs MOLN Comparison

Compare HNVR & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanover Bancorp Inc.

HNVR

Hanover Bancorp Inc.

HOLD

Current Price

$23.20

Market Cap

153.5M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$3.78

Market Cap

143.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HNVR
MOLN
Founded
2008
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Commercial Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
153.5M
143.3M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
HNVR
MOLN
Price
$23.20
$3.78
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$24.50
$8.38
AVG Volume (30 Days)
75.5K
6.1K
Earning Date
04-27-2026
05-12-2026
Dividend Yield
1.72%
N/A
EPS Growth
N/A
N/A
EPS
0.25
N/A
Revenue
N/A
N/A
Revenue This Year
$35.49
N/A
Revenue Next Year
$8.61
$374.07
P/E Ratio
$93.24
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.91
$3.41
52 Week High
$24.55
$5.36

Technical Indicators

Market Signals
Indicator
HNVR
MOLN
Relative Strength Index (RSI) 49.48 47.83
Support Level $21.89 $3.61
Resistance Level $24.34 $4.01
Average True Range (ATR) 0.76 0.12
MACD -0.05 0.01
Stochastic Oscillator 32.89 38.75

Price Performance

Historical Comparison
HNVR
MOLN

About HNVR Hanover Bancorp Inc.

Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: